Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease in Positive Phase 2 Trial
- Monday, January 11, 2021, 7:01
- Finance
- Add a comment
INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ — Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer’s disease…
About the Author
adminasapcorp has written 41558 stories on this site.